Norges Bank Spring Works Therapeutics, Inc. Transaction History

Norges Bank

$716 Trillion
Q3 2024

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$36.06 - $47.62 $10.1 Million - $13.3 Million	280,343 New	280,343 $10.6 Million
Q4 2023 Feb 09, 2024	BUY	$18.94 - $37.24 $6.4 Million - $12.6 Million	337,833 New	337,833 $12.3 Million
Q3 2023 Nov 13, 2024	BUY	$23.12 - $31.38 $6.19 Million - $8.4 Million	267,833 New	267,833 $6.19 Million
Q3 2023 Nov 13, 2023	SELL	$23.12 - $31.38 $8.27 Million - $11.2 Million	-357,694 Closed	0 $0
Q2 2023 Aug 14, 2024	SELL	$23.15 - $32.71 $289,606 - $409,202	-12,510 Reduced 4.46%	267,833 $7.02 Million
Q2 2023 Aug 14, 2023	SELL	$23.15 - $32.71 $11.9 Million - $16.7 Million	-511,893 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$24.97 - $34.05 $6.69 Million - $9.12 Million	267,833 New	267,833 $6.89 Million
Q4 2022 Feb 14, 2023	BUY	$21.73 - $28.72 $7.77 Million - $10.3 Million	357,694 New	357,694 $9.3 Million
Q3 2022 Nov 13, 2023	BUY	$24.1 - $39.66 $8.62 Million - $14.2 Million	357,694 New	357,694 $10.2 Million
Q2 2022 Aug 14, 2023	BUY	$18.36 - $60.07 $9.4 Million - $30.7 Million	511,893 New	511,893 $12.6 Million
Q1 2022 May 12, 2023	BUY	$48.97 - $65.46 $28.9 Million - $38.7 Million	590,671 Added 165.13%	948,365 $53.5 Million
Q1 2022 May 09, 2022	SELL	$48.97 - $65.46 $28.1 Million - $37.6 Million	-573,781 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$53.3 - $75.84 $30.6 Million - $43.5 Million	573,781 New	573,781 $35.6 Million
Q3 2021 Nov 14, 2022	BUY	$62.66 - $88.26 $31.1 Million - $43.8 Million	496,343 New	496,343 $31.5 Million
Q3 2021 Nov 05, 2021	SELL	$62.66 - $88.26 $33.1 Million - $46.7 Million	-528,966 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$67.45 - $85.63 $35.7 Million - $45.3 Million	528,966 New	528,966 $43.6 Million
Q2 2021 Aug 10, 2021	SELL	$67.45 - $85.63 $29.4 Million - $37.4 Million	-436,335 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$65.1 - $93.59 $28.4 Million - $40.8 Million	436,335 New	436,335 $32.1 Million
Q1 2021 May 07, 2021	SELL	$65.1 - $93.59 $30.7 Million - $44.1 Million	-470,992 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$48.36 - $77.92 $22.8 Million - $36.7 Million	470,992 New	470,992 $34.2 Million
Q4 2020 Feb 10, 2021	SELL	$48.36 - $77.92 $12 Million - $19.4 Million	-249,012 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$36.14 - $51.99 $9 Million - $12.9 Million	249,012 New	249,012 $11.9 Million
Q3 2020 Nov 10, 2020	SELL	$36.14 - $51.99 $8.1 Million - $11.7 Million	-224,200 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$22.98 - $48.57 $5.15 Million - $10.9 Million	224,200 New	224,200 $9.42 Million
Q2 2020 Aug 07, 2020	SELL	$22.98 - $48.57 $4.6 Million - $9.71 Million	-200,000 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$20.44 - $41.21 $4.09 Million - $8.24 Million	200,000 New	200,000 $5.4 Million
Q1 2020 May 08, 2020	SELL	$20.44 - $41.21 $4.09 Million - $8.24 Million	-200,000 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$17.74 - $39.52 $3.55 Million - $7.9 Million	200,000 New	200,000 $7.7 Million
Q4 2019 Feb 12, 2020	SELL	$17.74 - $39.52 $3.55 Million - $7.9 Million	-200,000 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$18.8 - $27.82 $3.76 Million - $5.56 Million	200,000 New	200,000 $4.34 Million

Others Institutions Holding SWTX

# of Institutions

237

Shares Held

68.9M

Call Options Held

144K

Put Options Held

257K

Vanguard Group Inc Valley Forge, PA

6.71M
Shares

$244 Million
0.0% of portfolio
Black Rock Inc. New York, NY

5.62M
Shares

$204 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

3.84M
Shares

$140 Million
4.54% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.52M
Shares

$128 Million
0.01% of portfolio
Boxer Capital, LLC San Diego, CA

3.42M
Shares

$124 Million
5.82% of portfolio

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.27B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account